Table 2.
Study | Animal (strain) | Treatment | Administration | Dosage | Frequency | Age | Number | Follow up | Outcome |
||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Swollen joints | Infiltration immune cells | Bone | Effect | ||||||||||
Okamoto et al. [2005] | Rats (Lewis) | AIA | Fenofibrate | Oral | 10 mg/kg 100 mg/kg |
Daily | 7 weeks | – | 18 days | ↓* | ↓* | – | – |
Castillero et al. [2011] | Rats (Wistar) | AIA | Fenofibrate | Oral | 300 mg/kg | Daily | N = 16/16/16 | 15 days | ↓* | – | – | ||
Bloxham et al. [1990] | Rats (AHH/R) Rats (AP1/R2) |
AIA CIA |
Clobuzarit | Oral | 10 mg/kg 30 mg/kg 100 mg/kg 60 mg/kg |
Daily |
N = 5/5/5/5/5/5/5 N = 8/8/8/8/8/8/8 |
5 days 15 days |
↓ ↓ ↓* ↓* |
– | Radiographic assessment | 0.97* | |
Still et al. [2008] | Rats (Wistar) |
- | Bezafibrate | Subcutaneous injection | 10 mg/kg | Daily | 3 months | N = 15/15/15 | 12 weeks | – | – | Trabecular bone Cortical bone Bone mass |
0.55*
0.96* 0.13 |
Outcomes given as effect size (calculated with difference in outcomes for both groups divided by the standard deviation of the outcome).
p < 0.05; ↓, reduction, effect size cannot be determined.
AIA, adjuvant-induced arthritis; CIA, collagen-induced arthritis.